Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:57 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Dronabinol On the Pain Experience
NCT05820685 · The University of Texas Health Science Center, Houston · PHASE4 · terminated · last registry update 2025-06-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study concluded because of drug shortage” | – | Registry record, The University of Texas Health Science Center, Houston |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CNR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-05-26Results posted on the registry: Hospital for Special Surgery, New York, cannabidiol (NCT04749628)
- 2026-05-07Results posted on the registry: Eric Hollander, CBDV Compound + Placebo (NCT03848481)
- 2026-05-07Also stopped (terminated): Eric Hollander, CBDV Compound + Placebo (NCT03848481)
- 2026-05-06Phase 3 first posted: Mayo Clinic, Dronabinol + Placebo (NCT07570953)
- 2026-05-06Results posted on the registry: University of Washington, Dronabinol (NCT04374773)
- 2026-04-27Phase 3 first posted: Associação Pan-Americana Multidisciplinar de Endocanabinologia, CBD Isolate 100mg BID (NCT07552974)
- 2026-04-21Also stopped (terminated): Cardiol Therapeutics Inc., Cannabidiol, pharmaceutically produced with < 5 ppm THC + Placebo (NCT04615949)
- 2026-04-09Results posted on the registry: Centre for Addiction and Mental Health, Placebo + Nabilone (NCT04801641)
- 2026-04-09Also stopped (terminated): Centre for Addiction and Mental Health, Placebo + Nabilone (NCT04801641)
- 2026-03-27Also stopped (terminated): Incannex Healthcare Ltd, IHL-675A + Cannabidiol (NCT05942911)
- 2026-03-27Results posted on the registry: Staci Gruber, Ph.D., Full-Spectrum Cannabidiol + Single-Compound Cannabidiol (NCT02548559)
- 2026-03-27Results posted on the registry: Hospital for Special Surgery, New York, Dronabinol 5mg Cap (NCT04734080)
- 2026-03-16Results posted on the registry: Mclean Hospital, Cannabidiol (CBD) + Placebo (NCT05753007)
- 2026-03-16Also stopped (terminated): Mclean Hospital, Cannabidiol (CBD) + Placebo (NCT05753007)
- 2026-03-16Also stopped (suspended): University of California, San Diego, THC ~2.5% + THC ~5% (NCT05427630)
- 2026-03-13Also stopped (withdrawn): Baylor College of Medicine, Dronabinol Capsules + Placebo (NCT06834997)
- 2026-03-09Results posted on the registry: Harmony Biosciences Management, Inc., ZYN002 (NCT05149898)
- 2026-02-27Phase 3 first posted: University of Oxford, Cannabidiol (CBD) + Placebo (NCT07434973)
- 2026-02-20Phase 3 first posted: Benuvia Therapeutics Inc., Dronabinol Oral Solution (NCT07422311)
- 2026-01-16Results posted on the registry: Mayo Clinic, Cannabidiol + Placebo Administration (NCT05388058)
- 2026-01-08Phase 3 first posted: University of Oxford, CBD 100 mg/mL Oral Solution + Placeb (NCT07326124)
- 2025-12-09Results posted on the registry: Dartmouth-Hitchcock Medical Center, Marijuana + Dronabinol (NCT01964404)
- 2025-11-26Results posted on the registry: Yale University, CBD Day 1 + CBD Day 2 (NCT05076370)
- 2025-11-24Phase 3 first posted: Khon Kaen University, 10% urea lotion plus 1% cannabidiol + Control (NCT07245238)
- 2025-11-17Phase 3 first posted: Mayo Clinic, Dronabinol + Placebo (NCT07231965)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision